Signet-Ring Cell Adenocarcinoma of the Lung Associated with Fingolimod Treatment in a Patient with Multiple Sclerosis
Jesús Romero Imbroda1*, Teresa Sagrario Fustero2, Clementina del Canto Pérez3, Jerónimo Sánchez González4 and Marcos Altable Pérez5
1Neurology Department. Hospital Quirónsalud Málaga, Spain.
2Department of Ophthalmology, Medical IMBRAIN, Melilla, Spain.
3Department of Neurology, Medical IMBRAIN, Melilla, Spain.
4Department of Internal Medicine, Hospital El Ángel, Malaga, Spain.
5Department of Neurology, NeuroCeuta, Ceuta, Spain.
*Corresponding Author: Jesus Romero Imbroda Servicio de Neurología. Hospital Quironsalud Malaga. Avenida Imperio Argentina 1. 29004. Málaga, Spain.
DOI: https://doi.org/10.58624/SVOANE.2024.05.0141
Received: May 22, 2024 Published: June 11, 2024
Abstract
Fingolimod is a selective sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) as monotherapy, in cases of first-line treatment failure, or as a first option in aggressive forms. The appearance of neoplasms is among the infrequent side effects of treatment. This is a case report on an MS patient treated with Fingolimod who developed pulmonary signet-ring cell adenocarcinoma of the lung and features a discussion of the drug’s possible involvement in the development of these types of neoplasms.
Keywords: Fingolimod Treatment; Lung, Headache; Signet-Ring Cell Adenocarcinoma; Multiple Sclerosis
Citation: Imbroda JR, Fustero TS, del Canto Perez C, Gonzalez JS, Perez MA. Signet-Ring Cell Adenocarcinoma of the Lung Associated with Fingolimod Treatment in a Patient with Multiple Sclerosis. SVOA Neurology 2024, 5:3, 145-148.
